{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:57:59Z","timestamp":1793307479879,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n Fero","doi-asserted-by":"publisher","award":["BBASELGAFERO2022-01"],"award-info":[{"award-number":["BBASELGAFERO2022-01"]}],"id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00147"],"award-info":[{"award-number":["PI22\/00147"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00203"],"award-info":[{"award-number":["PI23\/00203"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"'la Caixa' Foundation","doi-asserted-by":"publisher","award":["LCF\/PR\/HR21\/00083"],"award-info":[{"award-number":["LCF\/PR\/HR21\/00083"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["2020-112892RB"],"award-info":[{"award-number":["2020-112892RB"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101142365"],"award-info":[{"award-number":["101142365"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["488\/C\/2019"],"award-info":[{"award-number":["488\/C\/2019"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PI21\/01547"],"award-info":[{"award-number":["PI21\/01547"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.trecan.2025.04.014","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:33:06Z","timestamp":1748302386000},"page":"790-805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunocytokines and cytokine neutralization for cancer immunotherapy"],"prefix":"10.1016","volume":"11","author":[{"given":"Pedro","family":"Berraondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez-Ria\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Eguren-Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Luri-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Risson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Gomis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2025.04.014_bb0005","series-title":"Encyclopedia of Immunobiology","article-title":"Molecular immunology","author":"Colonna","year":"2025"},{"key":"10.1016\/j.trecan.2025.04.014_bb0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the treatment of cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0020","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.trecan.2025.04.014_bb0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.04.014_bb0030","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.04.014_bb0035","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.trecan.2025.04.014_bb0040","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0045","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.ajpath.2020.05.007","article-title":"The surprising story of IL-2: from experimental models to clinical application","volume":"190","author":"Abbas","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0050","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2024.07.723","article-title":"Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis","volume":"35","author":"Martin-Lluesma","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0055","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","article-title":"Adjuvant interferon-alpha for the treatment of high-risk melanoma: an individual patient data meta-analysis","volume":"82","author":"Ives","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2017.01.004","article-title":"Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment","volume":"31","author":"Katlinski","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.04.014_bb0070","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0075","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-023-06797-9","article-title":"An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis","volume":"625","author":"LaMarche","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0080","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","article-title":"The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer","volume":"634","author":"Feng","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2021.09.004","article-title":"The interleukin-1 cytokine family members: role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapy","volume":"62","author":"Boersma","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.trecan.2025.04.014_bb0090","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3390\/ijms19082155","article-title":"Interleukin-1 beta \u2013 a friend or foe in malignancies?","volume":"19","author":"Bent","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2025.04.014_bb0095","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/2159-8290.CD-21-1115","article-title":"A therapeutically actionable protumoral axis of cytokines involving IL-8, TNFalpha, and IL-1beta","volume":"12","author":"Olivera","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.04.014_bb0100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","article-title":"Tumor cell-derived IL1beta promotes desmoplasia and immune suppression in pancreatic cancer","volume":"80","author":"Das","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn0327","article-title":"Hematopoietic aging promotes cancer by fueling IL-1\u237a-driven emergency myelopoiesis","volume":"386","author":"Park","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.trecan.2025.04.014_bb0110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ccell.2021.04.011","article-title":"Interleukin-1 in tumor progression, therapy, and prevention","volume":"39","author":"Garlanda","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.04.014_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0120","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/14728222.2023.2287574","article-title":"Interleukin-18 in cancer immunology and immunotherapy","volume":"27","author":"Cirella","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.trecan.2025.04.014_bb0125","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","article-title":"IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy","volume":"583","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0130","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/eji.201344130","article-title":"TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells","volume":"44","author":"Bellora","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0135","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1538-7445.AM2023-1850","article-title":"Abstract 1850: a first-in-class PD1-IL18 immunocytokine (BPT567) targets PD-1+ IL18R+ CD8+ T effector cells enriched in the tumor microenvironment and exhibits potent antitumor efficacy with excellent tolerability [abstract]","volume":"83","author":"Carralot","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/intimm\/6.1.157","article-title":"Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo","volume":"6","author":"Gately","year":"1994","journal-title":"Int. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0150","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood.V87.9.3877.bloodjournal8793877","article-title":"Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10","volume":"87","author":"Sgadari","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.04.014_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108189","article-title":"Novel strategies exploiting interleukin-12 in cancer immunotherapy","volume":"239","author":"Cirella","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.trecan.2025.04.014_bb0160","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/carcin\/bgy136","article-title":"Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells","volume":"39","author":"Hao","year":"2018","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.trecan.2025.04.014_bb0165","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41586-024-08510-w","article-title":"IL-27 elicits a cytotoxic CD8+ T cell program to enforce tumour control","volume":"639","author":"Breart","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0170","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41573-024-01053-9","article-title":"Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer","volume":"23","author":"Croft","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2025.04.014_bb0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-immunol-082423-040557","article-title":"TNF\/TNFR superfamily members in costimulation of T cell responses-revisited","volume":"43","author":"Watts","year":"2025","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0180","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.186.1.47","article-title":"4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses","volume":"186","author":"Shuford","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2025.04.014_bb0190","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.7150\/thno.41646","article-title":"Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death","volume":"10","author":"Otano","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.trecan.2025.04.014_bb0195","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.4049\/jimmunol.169.9.4882","article-title":"4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1","volume":"169","author":"Lee","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0200","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1600-065X.2011.01069.x","article-title":"Science gone translational: the OX40 agonist story","volume":"244","author":"Weinberg","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trecan.2025.04.014_bb0205","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-22-1029","article-title":"CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary","volume":"13","author":"Melero","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.04.014_bb0210","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/imt.15.32","article-title":"Targeting the T-cell co-stimulatory CD27\/CD70 pathway in cancer immunotherapy: rationale and potential","volume":"7","author":"van de Ven","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.trecan.2025.04.014_bb2015","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1038\/sj.onc.1203551","article-title":"Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors","volume":"19","author":"Hirano","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2025.04.014_bb0620","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/1078-0432.CCR-21-1888","article-title":"Therapeutic targeting of LIF overcomes macrophage-mediated immunosuppression of the local tumor microenvironment","volume":"29","author":"Hallett","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb2020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb2025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb2030","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102357","article-title":"Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors","volume":"35","author":"Zhang","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.trecan.2025.04.014_bb2040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb2035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.it.2025.01.001","article-title":"CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells","volume":"46","author":"Wen","year":"2025","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0225","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2025.04.014_bb0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/onc.2013.537","article-title":"Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer","volume":"34","author":"Xiang","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2025.04.014_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aae0482","article-title":"Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus","volume":"8","author":"Wu","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2025.04.014_bb0240","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/0008-5472.CAN-13-2534","article-title":"IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma","volume":"74","author":"Ma","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0245","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2025.04.014_bb0215","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-beta-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0250","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in cancer","volume":"134","author":"Massague","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.04.014_bb0255","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.it.2020.03.003","article-title":"Immunotherapeutic potential of TGF-beta inhibition and oncolytic viruses","volume":"41","author":"Groeneveldt","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0260","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi4613","article-title":"Transforming growth factor-beta1 in regulatory T cell biology","volume":"7","author":"Moreau","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0265","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1038\/s41467-023-39817-3","article-title":"Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment","volume":"14","author":"Haake","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.04.014_bb0270","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1172\/JCI91561","article-title":"NF-kappaB regulates GDF-15 to suppress macrophage surveillance during early tumor development","volume":"127","author":"Ratnam","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2025.04.014_bb0275","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0280","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.04.014_bb0285","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","article-title":"TNF-alpha and cancer cachexia: molecular insights and clinical implications","volume":"170","author":"Patel","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.trecan.2025.04.014_bb0290","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0295","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ijc.26094","article-title":"VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2","volume":"130","author":"Ziogas","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0300","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.04.014_bb0305","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2024.23094","article-title":"Ivonescimab plus chemotherapy in patients with EGFR variant non-small cell lung cancer\u2013reply","volume":"333","author":"Fang","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.trecan.2025.04.014_bb0310","doi-asserted-by":"crossref","first-page":"S804","DOI":"10.1016\/j.annonc.2024.08.1312","article-title":"1255MO A phase II safety and efficacy study of PM8002\/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"35","author":"Wu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0315","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.trecan.2025.04.014_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107836","article-title":"Interleukin-2 therapy of cancer-clinical perspectives","volume":"98","author":"Majidpoor","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0325","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1089\/jir.2022.0043","article-title":"A protease activatable interleukin-2 fusion protein engenders antitumor immune responses by interferon gamma-dependent and interferon gamma-independent mechanisms","volume":"42","author":"Norville","year":"2022","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0330","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade5686","article-title":"IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein","volume":"7","author":"Gaggero","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0335","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/1538-7445.AM2023-4434","article-title":"Abstract 4434: A PD-1-targeted, receptor-masked IL-2 immunocytokine with maintained potential to engage endogenous IL-2Ra drives selective stimulation of PD-1+ T cells and robust anti-tumor efficacy [abstract]","volume":"83","author":"Wu","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0340","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cbpa.2021.01.007","article-title":"Cytokine engineering for targeted cancer immunotherapy","volume":"62","author":"Bonati","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0345","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1038\/ncomms4016","article-title":"High efficiency cell-specific targeting of cytokine activity","volume":"5","author":"Garcin","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.04.014_bb0350","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3389\/fimmu.2020.02148","article-title":"A double edged sword role of interleukin-22 in wound healing and tissue regeneration","volume":"11","author":"Arshad","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0355","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41541-020-00211-5","article-title":"Specific targeting of IL-1beta activity to CD8+ T cells allows for safe use as a vaccine adjuvant","volume":"5","author":"Van Den Eeckhout","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.trecan.2025.04.014_bb0360","doi-asserted-by":"crossref","first-page":"21575","DOI":"10.1038\/s41598-021-00891-6","article-title":"Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE","volume":"11","author":"Cauwels","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2025.04.014_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003293","article-title":"Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication","volume":"9","author":"Van Den Eeckhout","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0370","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12943-023-01908-6","article-title":"A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state","volume":"22","author":"Van Lint","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0375","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0380","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0385","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1016\/j.apsb.2024.07.024","article-title":"Advancements and challenges in immunocytokines: A new arsenal against cancer","volume":"14","author":"Shi","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.trecan.2025.04.014_bb0390","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coi.2016.03.006","article-title":"Immunocytokines for cancer treatment: past, present and future","volume":"40","author":"Neri","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0395","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine.\u2019","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0405","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2025.04.014_bb0410","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/1078-0432.CCR-23-2658","article-title":"Obinutuzumab pretreatment as a novel approach to mitigate formation of anti-drug antibodies against cergutuzumab amunaleukin in patients with solid tumors","volume":"30","author":"Peters","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0415","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1200\/JCO.2009.27.8861","article-title":"Antitumor activity of hu14.18-IL2 in patients with relapsed\/refractory neuroblastoma: a Children\u2019s Oncology Group (COG) phase II study","volume":"28","author":"Shusterman","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0420","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00262-012-1286-5","article-title":"Phase II trial of hu14.18-IL2 for patients with metastatic melanoma","volume":"61","author":"Albertini","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2025.04.014_bb0425","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.V128.22.620.620","article-title":"DI-Leu16-IL2, an anti-CD20-interleukin-2 immunocytokine, is safe and active in patients with relapsed and refractory B-cell lymphoma: a report of maximum tolerated dose, optimal biologic dose, and recommended phase 2 dose [abstract]","volume":"128","author":"Lansigan","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.04.014_bb0430","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.trecan.2025.04.014_bb0435","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2197360","article-title":"Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rbetagamma-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition","volume":"12","author":"Codarri Deak","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2025.04.014_bb0440","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.trecan.2023.11.008","article-title":"Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy","volume":"10","author":"Hashimoto","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0445","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/2159-8290.CD-23-1263","article-title":"CD8-Targeted IL2 unleashes tumor-specific immunity in human cancer tissue by reviving the dysfunctional T-cell pool","volume":"14","author":"Kaptein","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.04.014_bb0450","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0455","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1200\/JCO.23.02082","article-title":"Bempegaldesleukin plus nivolumab versus sunitinib or cabozantinib in previously untreated advanced clear cell renal cell carcinoma: a phase III randomized study (PIVOT-09)","volume":"42","author":"Tannir","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0460","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005813","article-title":"First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma","volume":"11","author":"Strauss","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0465","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-10-2490","article-title":"A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma","volume":"17","author":"Rudman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0470","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9501","article-title":"Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and\/or nodal metastases [abstract]","volume":"42","author":"Hauschild","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0475","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/ncponc0426","article-title":"Technology insight: utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities","volume":"3","author":"Grunhagen","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0480","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1182\/blood-2024-198751","article-title":"Trial in progress: ST-067 (decoy-resistant IL-18) with teclistamab in multiple myeloma [abstract]","volume":"144","author":"Banerjee","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.04.014_bb0485","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2326-6066.CIR-22-0373","article-title":"Intratumoral gene transfer of mRNAs encoding IL12 in combination with decoy-resistant IL18 improves local and systemic antitumor immunity","volume":"11","author":"Cirella","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0490","article-title":"mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy","volume":"4","author":"Olivera","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2025.04.014_bb0495","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2025.04.014_bb0500","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/2326-6066.CIR-23-0706","article-title":"Unleashing natural IL18 activity using an anti-IL18BP blocker induces potent immune stimulation and antitumor effects","volume":"12","author":"Menachem","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0505","first-page":"A812","article-title":"SRK-181, a latent TGFb1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors [abstract]","volume":"10","author":"Yap","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0510","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8456","article-title":"Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape","volume":"12","author":"Martin","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2025.04.014_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2025.04.014_bb0520","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-beta pathway","volume":"14","author":"Kim","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0525","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000433","article-title":"Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1\/TGF-betaRII agent: status of preclinical and clinical advances","volume":"8","author":"Lind","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0530","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","article-title":"Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: a randomized, open-label, phase 3 trial","volume":"18","author":"Cho","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0535","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2023.09.1452","article-title":"Bintrafusp alfa with CCRT followed by bintrafusp alfa versus placebo with CCRT followed by durvalumab in patients with unresectable stage III NSCLC: a phase 2 randomized study","volume":"19","author":"Vokes","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0540","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.trecan.2025.04.014_bb0545","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12012-014-9297-4","article-title":"Cardiac safety of TGF-beta receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study","volume":"15","author":"Kovacs","year":"2015","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100755","article-title":"New advances in cancer therapy targeting TGF-beta signaling pathways","volume":"31","author":"Shou","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.trecan.2025.04.014_bb0555","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cell.2019.12.030","article-title":"Cryo-EM reveals integrin-mediated TGF-beta activation without release from latent TGF-beta","volume":"180","author":"Campbell","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.04.014_bb0560","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint","volume":"11","author":"Wischhusen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0565","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes?","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.trecan.2025.04.014_bb0570","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdn054","article-title":"A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer","volume":"19","author":"Brown","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0575","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0580","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0585","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.04.014_bb0590","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0595","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San-Miguel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.04.014_bb0600","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0605","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00262-024-03899-9","article-title":"Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study","volume":"74","author":"Chen","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2025.04.014_bb0610","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1200\/JCO.2024.42.16_suppl.9538","article-title":"Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma [abstract]","volume":"42","author":"Weber","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100530","article-title":"Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors","volume":"7","author":"Borazanci","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.trecan.2025.04.014_bb0625","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-019-1130-6","article-title":"Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring","volume":"569","author":"Shi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0630","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2217\/fon-2020-1098","article-title":"Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design","volume":"17","author":"Garrido","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0635","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.23.00910","article-title":"Canakinumab as adjuvant therapy in patients with completely resected non-small-cell lung cancer: results from the CANOPY-A double-blind, randomized clinical trial","volume":"42","author":"Garon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.04.014_bb0640","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1474319","article-title":"Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study","volume":"7","author":"Isambert","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2025.04.014_bb0645","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1158\/0008-5472.CAN-18-0413","article-title":"IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer","volume":"78","author":"Wu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0650","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1038\/s41598-022-10700-3","article-title":"Supporting the gastrointestinal microenvironment during high-dose chemotherapy and stem cell transplantation by inhibiting IL-1 signaling with anakinra","volume":"12","author":"Wardill","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2025.04.014_bb0655","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","article-title":"A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer","volume":"103","author":"Rossi","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0660","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-19-3176","article-title":"Inhibition of IL1beta by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial","volume":"80","author":"Wong","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0665","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41416-022-01893-5","article-title":"Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology","volume":"127","author":"Lythgoe","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107451","volume":"189","author":"Paz-Ares","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0675","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ccell.2024.10.014","article-title":"Interleukin-1alpha release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity","volume":"42","author":"Hanggi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.04.014_bb0680","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291772","article-title":"Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors","volume":"18","author":"Fujikawa","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2025.04.014_bb0685","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","article-title":"Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma","volume":"38","author":"Noel","year":"2020","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2025.04.014_bb0690","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.04.014_bb0695","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.04.014_bb0700","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0705","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13058-019-1243-8","article-title":"A window-of-opportunity trial of the CXCR1\/2 inhibitor reparixin in operable HER-2-negative breast cancer","volume":"22","author":"Goldstein","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.trecan.2025.04.014_bb0710","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-022-00557-6","article-title":"Emerging principles of cytokine pharmacology and therapeutics","volume":"22","author":"Saxton","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2025.04.014_bb0715","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","article-title":"Potentiating adoptive cell therapy using synthetic IL-9 receptors","volume":"607","author":"Kalbasi","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.04.014_bb0720","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325001104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325001104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:38:48Z","timestamp":1762623528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803325001104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":149,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2405803325001104"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2025.04.014","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunocytokines and cytokine neutralization for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2025.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}